Results 1 - 25 from 140 for "antibiotice"
-
Antibiotice Iasi Ends Jan-Sept 2024 with RON511M Revenues, Up 7%. Net Profit Rises 15% To RON88M
11.15.2024
Romanian drug manufacturer Antibiotice Iasi, in which the Romanian state hold 53%, registered RON511 million revenues in the first nine months of 2024, up 15% annually, while net profit went up by 15% more
-
Antibiotice Iasi Aims to Invest RON850M by 2030
10.02.2024
Romanian drug manufacturer Antibiotice Iasi has a RON850 million investment plan until 2030, covered through a funding mix, made up of cohesion funds, state aid, PNRR funds and EIB loan, stated more
-
BET Index Of Bucharest Stock Exchange Includes Antibiotice And Premier Energy As Of Sept 23
09.23.2024
The BET index, the main index of the Bucharest Stock Exchange (BVB), is welcoming two new companies: Antibiotice Iasi (ATB) and Premier Energy (PE), starting September 23, 2024. more
-
Antibiotice Iasi Export Revenue Doubles In H1 2024 Vs H1 2020
08.21.2024
Antibiotice Iasi (ATB.RO), the largest Romanian-held drug producer, posted RON150 million revenue from exports in the first half of 2024, an increase of 25% on the year-ago period. more
-
Antibiotice Iasi Reports RON74M Net Profit For H1/2024, Up 20% YoY
08.14.2024
Romanian-owned drug manufacturer Antibiotice Iasi (stock symbol: ATB) ended the first half of 2024 with net profit of RON74 million, up 20% on the year, while its revenue rose by 8% to RON380 million, more
-
Romanian-Held Pharmaceutical Manufacturer Antibiotice To Get EUR100M In EU Funding To Make Critical Drugs
06.06.2024
Antibiotice Iasi, (ATB.RO) the largest Romanian-owned pharmaceutical producer, will receive EUR100 million in EU funding for the production of drugs such as antibiotics, for which there are no more
-
Antibiotice Iasi Records 13% Revenue Growth in Q1/2024. Net Profit Climbs 68%
05.15.2024
Antibiotice Iasi, the largest Romanian-owned drug manufacturer, saw revenues reach an overall RON192.5 million level, 13% higher than in the year-earlier period. more
-
Antibiotice Iasi Eyes RON850M Investments by 2030
04.30.2024
Antibiotice Iasi, the largest Romanian-held drug maker, has a total RON850 million investment plan between 2023-2030 to reach RON1 billion turnover at the end of this period. more
-
Antibiotice Iasi Commissions 2.5 MW Photovoltaic Plant
03.28.2024
Pharma manufacturer Antibiotice Iasi has commissioned a 2.5 MW photovoltaic plant, with total investments in the project amounting to RON11.8 million, of which RON4.07 million were granted by the more
-
Antibiotice Iasi Wants to Cross RON100M Profit Threshold in 2024
03.25.2024
Antibiotice Iasi, the biggest Romanian-held drug manufacturer, wants to reach RON104 million net profit in 2024, up 28% from 2023, in line with its income and expenses budget. more
-
Antibiotice Iasi Seeks To Pay Dividends Of RON31M From 2023 Profit
03.14.2024
Pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) is summoning its shareholders to approve, among others, the distribution of RON31 million from the company's 2023 profit under the form of more
-
Antibiotice Iasi's Net Profit More Than Doubles YoY To RON80.7M In 2023
02.28.2024
Pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) ended 2023 with net profit of RON80.7 million, up 109.5% from 2022, and a turnover of RON600.8 million, up 7.2% on the year, in line with more
-
Antibiotice Iasi Launches New Vet Product Range
02.09.2024
Antibiotice Iasi, the largest Romanian-held pharma producer, is launching eight veterinary products in the range of nutritional supplements, complementing the company’s veterinary prescription more
-
Antibiotice Iasi Calls Shareholders To Approve Contracting RON35M Credit Facility From Banca Transilvania
01.25.2024
The Board of Directors of pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) announced in a stock market report on Thursday (Jan. 25, 2024) that it has called shareholders for a meeting on February more
-
Antibiotice Iasi Shares To Be Included In MSCI Indices Starting With 1st Trading Day Of Dec 2023
11.16.2023
The Bucharest Stock Exchange has announced Wednesday evening that the shares of Antibiotice (ATB.RO), the Romanian manufacturer of generic drugs, listed on the local capital market for 26 years, will more
-
Antibiotice Iasi Ends 9M 2023 with RON463.4M Turnover, Up 28%, RON76M Net Profit, More than Double the 9M 2022 Level
11.15.2023
Romanian state-owned pharma producer Antibiotice Iasi for the first nine months of 2023 reported RON463.4 million turnover, up 28%, and RON76 million net profit, more than doubled the RON30 million more
-
First Loan Via InvestEU In Romania Goes To Antibiotice Iasi For New Plant
11.10.2023
Pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) has signed a EUR25 million loan agreement with the European Investment Bank (EIB), which will help finance the construction of new production more
-
Antibiotice Iasi Shareholders OK EUR25M Funding from EIB
10.31.2023
The extraordinary general meeting of shareholders convened by drug maker Antibiotice Iasi on October 30 approved the signing of a financing contract worth EUR25 million euro, i.e. RON23 million more
-
Antibiotice Iasi Looks at New Export Markets
10.05.2023
Antibiotic Iasi, the biggest Romanian-held drug producer, is mulling new export markets, including Nordic ones, where it is trying to already develop its first local partnerships. more
-
Antibiotice Iasi Calls Shareholders To Approve EUR25M Financing Contract With The Romanian State
09.16.2023
Romanian state-owned pharmaceutical manufacturer Antibiotice (ATB.RO) has called shareholders for a general meeting on October 30, 2023 to secure approval for the conclusion of a financing contract more
-
Antibiotice Iasi Ends First Half With 83% Rise In Profit
08.14.2023
Antibiotice Iasi (ATB.RO), the most important Romanian producer of generic drugs, recorded sales of RON315.9 million in the first half of 2023, a 27% increase compared with the first half of 2022, more
-
Antibiotice Iasi Gets RON4.1M Funding For Photovoltaic Park
06.07.2023
Antibiotice Iasi (ATB.RO), Romania’s largest producer of generic drugs, on Wednesday notified the Bucharest Stock Exchange of having received RON4.08 million from the Ministry of European Investment more
-
SIF Oltenia Buys 2.4% Of Antibiotice Iasi Shares In RON9.3M Deal
05.18.2023
Antibiotice Iasi (ATB.RO), Romania’s most important generic drug manufacturer, on Thursday (May 18) informed the Bucharest Stock Exchange (BVB) that SIF Oltenia (SIF5.RO), its second largest more
-
Antibiotice Iasi Gets RON85M State Aid For Production And Logistics Facility
05.18.2023
Romania’s most important generic drug manufacturer Antibiotice Iasi (ATB.RO) has received from the Romanian government the approval for the funding of a project for manufacturing, packaging and more
-
Antibiotice Iasi Posts RON178M Sales in 1Q/2023, Up around 40%, Sees Net Profit Almost Triple To RON22M
05.12.2023
Romanian pharma producer Antibiotice Iasi ended the first quarter of 203 with RON178 million sales, up around 40%, and RON22 million net profit, almost triple the level of the year-earlier period. more